Pityriasis Rubra Pilaris Successfully Treated with Infliximab

Ruíz‐Genao, Diana; López‐Estebaranz, José Luis; Naz-Villalba, E.; Villegas, Reyes Gamo; Calzado-Villarreal, Leticia; Moraleda, Fernando Pinedo

doi:10.2340/00015555-0308

Cited by 26 publications

(22 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9 Presently, the most recent successful infliximab use has been shown in a patient after ineffective pretreatment with cyclosporine and acitretin therapy. 10 Though infliximab has shown clinical efficacy in the above listed cases, Lu et al 11 presented a case unresponsive to combination infliximab and acitretin therapy. Of note, the first case of type III classic juvenile-onset PRP successfully treated with infliximab has recently been reported, 12 and the first two cases of type I PRP treated successfully with combination etanercept and acitretin therapy have emerged.…”

Section: Discussionmentioning

confidence: 97%

Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: Case report and review of the literature on biologic therapy

Müller

Gattringer

Zelger

et al. 2008

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: Case report and review of the literature on biologic therapy

Müller

Gattringer

Zelger

et al. 2008

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…in 2003 led to a clinical response of <75% within 3 days to 2 weeks after the first infusion of infliximab using a dose of 5 mg/kg bodyweight. Overlooking the several case reports, in small case series and reviews of the literature, especially in severe cases of PRP or when other therapeutic options already failed to be of any benefit, infliximab is reported to be an effective alternative treatment . Moreover, the combination of infliximab with methotrexate or acitretin has been described as an additional possibility.…”

Section: Treatment With Biologics and Small Moleculesmentioning

confidence: 99%

Pityriasis rubra pilaris: algorithms for diagnosis and treatment

Roenneberg

Biedermann

2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease that affects men and women of all ages and also children. The clinical appearance of PRP is highly variable, as is the individual prognosis. Therefore, stratifying PRP into six disease subtypes represents a first step to personalized medicine for this rare inflammatory skin disease. The next step should be to associate specific therapeutic strategies with these subtypes of PRP. However, no randomized, controlled trials on the treatment of PRP have been performed. Consequently, the actual treatment algorithm for PRP will be based on clinical experience, small case series and case reports. The majority of published evidence is on type I PRP, whereas the treatment experience for other clinical types of PRP is still sparse and has to be gained. Nevertheless, it is now time to start developing valid algorithms as a basis for the diagnosis and treatment of PRP based on the data available. This review makes use of algorithms developed in psoriasis and atopic eczema and puts together recent insights into the pathogenesis, diagnosis and treatment experience of PRP. The innovative intention of this appraisal is to develop a structured algorithm for PRP treatment that should be further developed going forward.

show abstract

“…Between 2003 and 2010, 13 patients have been published who underwent successful treatment with infliximab with 2–8 infusions at a dose of 5 mg/kg in variable intervals [23,24,25,26,27]. Eight of these patients had adjunctive treatment with acitretin, cyclosporine, methotrexate, UVB, and systemic or topical glucocorticosteroids.…”

Section: Discussionmentioning

confidence: 99%

Pityriasis Rubra Pilaris: Treatment with Biologics – A New Promising Therapy?

2012

View full text Add to dashboard Cite

Pityriasis rubra pilaris (PRP) includes a spectrum of rare chronic inflammatory disorders with papulosquamous eruptions of unknown cause. Different etiologies have been proposed such as vitamin A metabolism dysfunction, association with autoimmune disorders, infection or malignancies. However, PRP seems to be a polygenic skin disorder. Classical systemic treatment is empirical and includes retinoids and methotrexate; however, only few series on treatments exist. Recently there has been an increasing number of reports documenting that new biologicals and in particular TNF-α blockers are safe and effective.

show abstract

Pityriasis Rubra Pilaris Successfully Treated with Infliximab

Cited by 26 publications

References 10 publications

Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: Case report and review of the literature on biologic therapy

Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: Case report and review of the literature on biologic therapy

Pityriasis rubra pilaris: algorithms for diagnosis and treatment

Pityriasis Rubra Pilaris: Treatment with Biologics – A New Promising Therapy?

Contact Info

Product

Resources

About